recombinant humanized anti-interleukin-6 receptor monoclonal antibody
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 18, 2022 (NCT05345522)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-6ANTAGONIST
IL6
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05345522 | Phase 2 | Apr 18, 2022 | Chinese Academy of Medical Sciences, Government of China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Government of China | Government | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1